Efol ER Capsule (Extended Release)
Capsule (Extended Release)
Beximco Pharmaceuticals Ltd.Weight:
150 mg+0.5 mg+61.8 mgbest Price:
৳ 2.51Generic
Ferrous Sulfate + Folic Acid + Zinc Sulfate
Pharmacology
Each timed-release capsule contains- Ferrous Sulphate BP 150 mg (equivalent to 47 mg Iron) Folic Acid BP 500 mcg and Zinc Sulphate Monohydrate USP 61.80 mg (equivalent to 22.50 mg Zinc.)
Dosage Administration
Do not use in patients hypersensitive to the components of the product or those with iron overload.
Contraindications
Use of any drug during the first trimester of pregnancy should be avoided if possible. Thus administration of Iron during the first trimester requires definite evidence of Iron deficiency where inadequate diet calls for supplementary Zinc and Folic acid is justified during the remainder of the pregnancy.
Side Effects
Care should be taken in patients who may develop Iron overloads, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Failure to respond to treatment may indicate other causes of anaemia and should be further investigated. Iron & Zinc chelate with tetracycline and absorption of all three agents may be impaired. The absorption of Zinc may be reduced in the presence of Iron. Absorption of Iron may be impaired by penicillamine and by antacids. Such potential interactions can be reduced by separating the administration of each product by several hours. In patients with renal failure a risk of Zinc accumulation could exist.
Pregnancy And Lactation
Dark stools are usual during iron therapy and nausea and other symptoms of gastrointestinal irritation such as anorexia, vomiting, discomfort, constipation and diarrhoea are sometimes encountered. Zinc may also produce a gastrointestinal upset. These timed-release capsules are designed to reduce the possibility of gastrointestinal irritation. There have been rare reports of allergic reactions
Storage Conditions
Care should be taken in patients who may develop Iron overloads, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Failure to respond to treatment may indicate other causes of anaemia and should be further investigated. Iron & Zinc chelate with tetracycline and absorption of all three agents may be impaired. The absorption of Zinc may be reduced in the presence of Iron. Absorption of Iron may be impaired by penicillamine and by antacids. Such potential interactions can be reduced by separating the administration of each product by several hours. In patients with renal failure a risk of Zinc accumulation could exist.
Over The Counter Products
